AnaBios supplies high-quality human tissues and cells sourced from a network of hospitals and organ procurement organizations, preserving physiological function through proprietary methods and streamlined logistics.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preclinical drug development often depends on animal models that fail to accurately predict human efficacy and safety, leading to costly late‑stage failures and delayed clinical progress.
Solution
AnaBios supplies high‑quality human tissues and cells sourced from a nationwide network of hospitals and organ procurement organizations, preserving physiological function through proprietary preservation methods and streamlined logistics. The company offers standardized ex vivo human cardiac, CNS, and peripheral nervous system platforms that enable functional assays directly on authentic human biology. These assays generate quantitative efficacy, potency, selectivity, and safety data early in the discovery pipeline, reducing translational gaps and informing dosing and risk‑mitigation decisions before clinical trials. By delivering reproducible human‑relevant data, AnaBios helps drug‑discovery teams prioritize the most promising candidates, lower development costs, and accelerate timelines to the clinic.
Target Audience
Primary customers are pharmaceutical and biotech companies conducting preclinical drug discovery and development, particularly teams focused on cardiovascular, pain, and CNS therapeutic areas.
Features
- Access to ethically sourced human tissue and cell samples from healthy and diseased donors across multiple organ systems
- Proprietary preservation and logistics protocols that maintain native physiological function for ex vivo assays
- Functional assay platforms (e.g., cardiac, pain, itch, CNS) that provide potency, selectivity, and toxicity readouts in human tissue
- Integrated omics capabilities (gene expression, proteomics, metabolomics) for target validation and mechanism‑of‑action studies
- Rapid turnaround (1–6 weeks) with typical studies using 1–3 donor samples
- Data delivered in standardized reports compatible with regulatory expectations and downstream modeling